Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Tracon Pharmaceuticals Inc (TCON) USD0.001

Sell:$4.65 Buy:$4.95 Change: $0.42 (9.29%)
NASDAQ:0.37%
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:$4.65
Buy:$4.95
Change: $0.42 (9.29%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:$4.65
Buy:$4.95
Change: $0.42 (9.29%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Contact details

Address:
4350 La Jolla Village Dr Ste 800
SAN DIEGO
92122-1247
United States
Telephone:
+1 (858) 5500780
Website:
www.traconpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TCON
ISIN:
US89237H2094
Market cap:
$57.74 million
Shares in issue:
13.18 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Charles Theuer
    President, Chief Executive Officer, Principal Financial Officer, Director
  • Bonne Adams
    Executive Vice President - Clinical Operations
  • Sharon Real
    Executive Vice President - Product Development
  • Scott Brown
    Chief Accounting Officer, Principal Accounting Officer
  • Mark Wiggins
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.